References
- Kalinderi K, Bostantjopoulou S, Katsarou Z, Fidani L. TLR9-1237 T/C and TLR2-194 to -174 del polymorphisms and the risk of Parkinson's disease in the Greek population: a pilot study. Neurol Sci 2013;34(5):679–82.
- Beraud D, Twomey M, Bloom B, et al. Alpha-synuclein alters toll-like receptor expression. Front Neurosci 2011;5:80–90.
- Gao HM, Zhou H, Hong JS. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol Sci 2012;33(6):295–303.
- Zimprich A. Genetics of Parkinson's disease and essential tremor. Curr Opin Neurol 2011;24(4):318–23.
- Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics 2010;7(4):354–65.
- Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 2010;11(5):373–84.
- Wang YL, Tan MS, Yu JT, et al. Toll-like receptor 9 promoter polymorphism is associated with decreased risk of Alzheimer's disease in Han Chinese. J Neuroinflamm 2013;10(1):101.
- Dominguez-Mozo MI, Garcia-Montojo M, Lopez-Cavanillas M, et al. Toll-like receptor-9 in Spanish multiple sclerosis patients: an association with the gender. Eur J Neurol 2014;21(3):537–40.
- Carty M, Bowie AG. Evaluating the role of toll-like receptors in diseases of the central nervous system. Biochem Pharmacol 2011;81(7):825–37.
- Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21(3):383–421.
- Ros-Bernal F, Hunot S, Herrero MT, et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci U S A 2011;108(16):6632–7.
- Wei XS, Wei CD, Tong YQ, et al. Single nucleotide polymorphisms of toll-like receptor 7 and toll-like receptor 9 in hepatitis C virus infection patients from central China. Yonsei Med J 2014;55(2):428–34.
- Roszak A, Lianeri M, Sowinska A, Jagodzinski PP. Involvement of toll-like receptor 9 polymorphism in cervical cancer development. Mol Biol Rep 2012;39(8):8425–30.
- Liu B, Xie J. Increased dopamine release in vivo by estradiol benzoate from the central amygdaloid nucleus of Parkinson's disease model rats. J Neurochem 2004;90(3):654–8.
- Pandey S, Agrawal DK. Immunobiology of toll-like receptors: emerging trends. Immunol Cell Biol 2006;84(4):333–41.
- Pandey S, Mittal B, Srivastava M, et al. Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol Biol Rep 2011;38(7):4715–21.
- Harper SJ, Wilkie N. MAPKs: new targets for neurodegeneration. Expert Opin Ther Targets 2003;7(2):187–200.
- Ghosh A, Roy A, Liu X, et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2007;104(47):18754–9.
- Cheng PL, Eng HL, Chou MH, et al. Genetic polymorphisms of viral infection-associated toll-like receptors in Chinese population. Transl Res 2007;150(5):311–8.